Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients

  title={Estimating a normal reference range for serum B‐cell maturation antigen levels for multiple myeloma patients},
  author={Scott Kristian Jew and Sean Elliott Bujarski and Camilia M. Soof and Haiming Chen and Tahmineh Safaie and Mingjie Li and Eric Sanchez and Cathy S. Wang and Marsiye Emamy-Sadr and Regina Swift and Ashkon Rahbari and Saurabh Patil and Eric Souther and Tanya M. Spektor and James R. Berenson},
  journal={British Journal of Haematology},
The serum B‐cell maturation antigen (sBCMA) has been identified as a novel serum biomarker for patients with multiple myeloma. However, no study has yet established a reference range for sBCMA levels. Its levels were determined in 196 healthy subjects and showed a right‐tailed distribution with a median value of 37·51 ng/ml with a standard deviation of 22·54 ng/ml (range 18·78–180·39 ng/ml). Partitioning of subgroup reference ranges was considered but determined to be irrelevant. A non… Expand
2 Citations
Focus on monoclonal antibodies targeting B‐cell maturation antigen (BCMA) in multiple myeloma: update 2021
The present results have laid the groundwork for the ongoing or upcoming clinical trials with combinatory regimens, which have always been a cornerstone in the treatment of MM. Expand
Anti-body building: The exercise of advancing immune based myeloma therapies.
A look at the current landscape of "off-the-shelf" antibody-based therapies in myeloma and peer into the next wave of multi-functional targeted agents. Expand


Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Serum BCMA levels were found to be higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma patients than in healthy subjects, and levels correlated with the change in tumour volume in response to melphalan or cyclophosphamide with bortezomib. Expand
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
Serum B-cell maturation antigen levels did not show any dependence on renal function and maintained independent significance when tested against other known prognostic markers for multiple myeloma such as age, serum β2 microglobulin, hemoglobin, and bone disease. Expand
Baseline and Increases in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Relapsed/Refractory Multiple Myeloma Patients Undergoing New Treatments
The relationship between progression free survival (PFS) and changes in weekly levels of sBCMA, sM-protein and serum free light chain (sFLC) during the first cycle of a new treatment among relapsed/refractory (RR)MM patients is analyzed. Expand
Non-secretory multiple myeloma: from biology to clinical management
True forms of multiple myeloma, meaning MM that secretes no monoclonal proteins whatsoever, constitute a distinct entity that is reviewed; definition of NSMM using current detection methods, discuss the biology underpinning NSMM development, and share recommendations for how NSMM should be managed clinically with respect to detection, treatment, and monitoring. Expand
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Several aspects of disease response assessment are clarified, along with endpoints for clinical trials, and future directions for disease response assessments are highlighted, to allow uniform reporting within and outside clinical trials. Expand
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple Myeloma
Investigation of BCMA as a target for therapeutic intervention in multiple myeloma (MM) were initiated in 2007, using cSG1 as a naked antibody as well as an Ab–drug conjugate (ADC) targeting BCMA, ultimately leading to ongoing clinical studies for previously treated MM patients. Expand
Multiple myeloma
An increasing proportion of patients are achieving lasting remissions, raising the possibility of cure for this disease, and success will probably depend on using combinations of effective agents and treating patients in the early stages of disease, such as patients with smouldering multiple myeloma. Expand
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Together, shedding of BCMA by γ-secretase controls plasma cells in the bone marrow and yields a potential biomarker for B-cell involvement in human autoimmune diseases. Expand
The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed.
It is shown that the BCMA gene is organized into three exons and its major initiation transcription site is located 69 nucleotides downstream of a TATA box, suggesting a role for this gene in the B-cell developmental process. Expand
Reference intervals for calcium, phosphate, and alkaline phosphatase as derived on the basis of multichannel-analyzer profiles.
The mean concentrations of calcium and phosphate decreased with increasing age in both sexes, except for an abrupt increase for women about the time of reaching menopause, and the mean alkaline phosphatase activity increased with age inboth sexes, reflecting a skewed frequency distribution. Expand